美麗田園醫療健康(02373.HK)香港發售股份獲超額認購22.12倍 發售價每股19.32港元
格隆匯1月13日丨美麗田園醫療健康(02373.HK)發佈公吿,公司全球發售4053.65萬股股份,其中中國香港發售股份1216.1萬股,國際發售股份2837.55萬股;發售價為每股發售股份19.32港元,每手買賣單位500股;摩根士丹利、海通國際及華泰國際為聯席保薦人;預期股份將於2023年1月16日於聯交所主板掛牌上市。
香港公開發售項下初步提呈發售的香港發售股份已獲非常大幅超額認購。公司已接獲合共6671份有效申請,相當於香港公開發售項下初步可供認購的發售股份總數約22.12倍。根據國際發售初步提呈發售的發售股份已獲適度超額認購,即根據國際發售初步可供認購的國際發售股份總數約4.7倍。基於發售價每股發售股份19.32港元,根據基石投資協議,基石投資者已認購合共2169.7萬股股份。
按發售價每股發售股份19.32港元計算,將收取的全球發售所得款項淨額估計約為3.872億港元(假設超額配股權未獲行使)。公司擬將所得款項淨額67.6%分配至擴張及升級集團的服務網絡,包括通過內生增長及收購擴展集團的傳統美容服務直營店網絡、在新一線城市擴展及升級醫療美容服務以及亞健康評估及干預服務的門店網絡,以及在上海市及北京市各自建立一家旗艦美麗與健康管理服務中心;10.2%將用於進行戰略併購加盟店;12.3%將分配至進一步投資於集團的信息技術系統;及9.9%將分配至營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.